<scp>BJP</scp> is linking its articles to the <scp>IUPHAR</scp>/<scp>BPS G</scp>uide to <scp>PHARMACOLOGY</scp>

McGrath, J.C.; Pawson, Adam J.; Sharman, Joanna L.; Alexander, Stephen P.H.

doi:10.1111/bph.13112

Cited by 9 publications

(10 citation statements)

References 7 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This includes details on PubMed ID statistics in curated GtoPdb content. The same post also shows how engagement with British Journal of Pharmacology (BJP) has extended the previous provision of live out-links ( 50 ), to now include in line links, rather than the previous method of adding separate tables to manuscripts.…”

Section: Collaborations Connectivity and Interoperabilitymentioning

confidence: 92%

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

Harding

Sharman

Faccenda

et al. 2017

Nucleic Acids Research

1,566

1,301

View full text Add to dashboard Cite

The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb, www.guidetopharmacology.org) and its precursor IUPHAR-DB, have captured expert-curated interactions between targets and ligands from selected papers in pharmacology and drug discovery since 2003. This resource continues to be developed in conjunction with the International Union of Basic and Clinical Pharmacology (IUPHAR) and the British Pharmacological Society (BPS). As previously described, our unique model of content selection and quality control is based on 96 target-class subcommittees comprising 512 scientists collaborating with in-house curators. This update describes content expansion, new features and interoperability improvements introduced in the 10 releases since August 2015. Our relationship matrix now describes ∼9000 ligands, ∼15 000 binding constants, ∼6000 papers and ∼1700 human proteins. As an important addition, we also introduce our newly funded project for the Guide to IMMUNOPHARMACOLOGY (GtoImmuPdb, www.guidetoimmunopharmacology.org). This has been ‘forked’ from the well-established GtoPdb data model and expanded into new types of data related to the immune system and inflammatory processes. This includes new ligands, targets, pathways, cell types and diseases for which we are recruiting new IUPHAR expert committees. Designed as an immunopharmacological gateway, it also has an emphasis on potential therapeutic interventions.

show abstract

Section: Collaborations Connectivity and Interoperabilitymentioning

confidence: 92%

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

Harding

Sharman

Faccenda

et al. 2017

Nucleic Acids Research

1,566

1,301

View full text Add to dashboard Cite

show abstract

“…To achieve this, the GtoPdb team and the CGTP editors collaborate with the Wiley publishers on what is, in effect, the automatic converting of (pre-tagged) sections of the database directly into the online CGTP PDF documents. The second initiative, also a collaboration with the BJP, involves marking-up tables of links (ToLs) for both regular papers and reviews ( 32 ). An example is a recent invited review on epigenetic pathway targets for the treatment of disease, which can be viewed at http://onlinelibrary.wiley.com/doi/10.1111/bph.12848/epdf (the ToLs are on the second page) ( 33 ).…”

Section: Connectivity Collaborationsmentioning

confidence: 99%

“…The invited review provided the curatorial starting point for the capture of new ligands and targets to populate the database and these were consequently surfaced as ToLs in the article. The third journal-to-database initiative is a logical extension of the previous two ( 32 ). This involves an updated version of the BJP instructions-to-authors that now includes recommendations on resolving the molecular identities of targets and ligands at the submission stage.…”

Section: Connectivity Collaborationsmentioning

confidence: 99%

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

Southan¹,

Sharman²,

et al. 2015

View full text Add to dashboard Cite

The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb, http://www.guidetopharmacology.org) provides expert-curated molecular interactions between successful and potential drugs and their targets in the human genome. Developed by the International Union of Basic and Clinical Pharmacology (IUPHAR) and the British Pharmacological Society (BPS), this resource, and its earlier incarnation as IUPHAR-DB, is described in our 2014 publication. This update incorporates changes over the intervening seven database releases. The unique model of content capture is based on established and new target class subcommittees collaborating with in-house curators. Most information comes from journal articles, but we now also index kinase cross-screening panels. Targets are specified by UniProtKB IDs. Small molecules are defined by PubChem Compound Identifiers (CIDs); ligand capture also includes peptides and clinical antibodies. We have extended the capture of ligands and targets linked via published quantitative binding data (e.g. Ki, IC50 or Kd). The resulting pharmacological relationship network now defines a data-supported druggable genome encompassing 7% of human proteins. The database also provides an expanded substrate for the biennially published compendium, the Concise Guide to PHARMACOLOGY. This article covers content increase, entity analysis, revised curation strategies, new website features and expanded download options.

show abstract

“…HO-1 is an antioxidative and cytoprotective enzyme, which degrades haem to biliverdin, iron ions and carbon monoxide (Maines, 1997). Previous studies indicated that overexpression of HO-1 reduced DGCR8 dimer formation and expression of DGCR8, which is a protein involved in miRNA processing and requires F I G U R E 7 Treatment with 1m-6 attenuates lipid accumulation and plaque formation in atherosclerosis-prone mice.…”

Section: Discussionmentioning

confidence: 99%

“…All experiments were designed to generate groups of equal size, using randomization and blinded analysis. Group sizes in each protocol were determined based on our previous studies, preliminary results and the power analysis (McGrath, Pawson, Sharman, & Alexander, 2015). All the data, including outliers, were included in data analysis and presentation.…”

Section: Methodsmentioning

confidence: 99%

A chalcone derivative, 1m‐6, exhibits atheroprotective effects by increasing cholesterol efflux and reducing inflammation‐induced endothelial dysfunction

Chen

Tsai

Tsao

et al. 2020

British J Pharmacology

View full text Add to dashboard Cite

Background and Purpose: Atherosclerosis, resulting from lipid dysregulation and vascular inflammation, causes atherosclerotic cardiovascular disease (ASCVD), which contributes to morbidity and mortality worldwide. Chalcone and its derivatives possess beneficial properties, including anti-inflammatory, antioxidant and antitumour activity with unknown cardioprotective effects. We aimed to develop an effective chalcone derivative with antiatherogenic potential. Experimental Approach: Human THP-1 cells and HUVECs were used as in vitro models. Western blots and real-time PCRs were performed to quantify protein, mRNA and miRNA expressions. The cholesterol efflux capacity was assayed by 3 H labelling of cholesterol. LDL receptor knockout (Ldlr −/−) mice fed a high-fat diet were used as an in vivo atherogenesis model. Haematoxylin and eosin and oil red O staining were used to analyse plaque formation.

show abstract

BJP is linking its articles to the IUPHAR/BPS Guide to PHARMACOLOGY

Cited by 9 publications

References 7 publications

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

A chalcone derivative, 1m‐6, exhibits atheroprotective effects by increasing cholesterol efflux and reducing inflammation‐induced endothelial dysfunction

Contact Info

Product

Resources

About